Table 11.5Subgroup analyses for any nephrotoxicity

SubgroupStudiesEpisodesRisk Ratio (M-H, Fixed, 95% CI)
(<1 favours monotherapy, >1 favours dual therapy)
Overall3764110.45 [0.35, 0.57]
Once daily aminoglycoside regimen615100.29 [0.13, 0.63]
Multiple daily aminoglycoside regimen3149010.47 [0.36, 0.61]

From: Initial Treatment: guideline chapter six

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.